Boston Scientific Corp. (NYSE:BSX)’s share price traded up 2% on Thursday . The stock traded as high as $24.31 and last traded at $24.29, with a volume of 5,405,102 shares changing hands. The stock had previously closed at $23.82.

Several equities analysts recently weighed in on the stock. JPMorgan Chase & Co. restated a “buy” rating on shares of Boston Scientific Corp. in a research report on Sunday, July 17th. TheStreet lowered shares of Boston Scientific Corp. from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. Benchmark Co. increased their price target on shares of Boston Scientific Corp. from $25.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, July 28th. Leerink Swann reaffirmed a “buy” rating on shares of Boston Scientific Corp. in a report on Friday, July 29th. Finally, BTIG Research downgraded shares of Boston Scientific Corp. from a “buy” rating to a “neutral” rating and set a $24.20 price objective on the stock. in a report on Monday, May 23rd. Six investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. Boston Scientific Corp. presently has an average rating of “Buy” and a consensus target price of $25.03.

The company has a 50 day moving average of $23.99 and a 200-day moving average of $21.45. The firm’s market capitalization is $33.01 billion.

Boston Scientific Corp. (NYSE:BSX) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.27 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.27. During the same period last year, the company earned $0.22 EPS. The business earned $2.13 billion during the quarter, compared to the consensus estimate of $2.05 billion. The business’s revenue was up 15.4% compared to the same quarter last year. Analysts predict that Boston Scientific Corp. will post $1.10 earnings per share for the current fiscal year.

In other news, SVP John Bradley Sorenson sold 2,500 shares of the stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $23.90, for a total transaction of $59,750.00. Following the transaction, the senior vice president now owns 12,615 shares of the company’s stock, valued at approximately $301,498.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael F. Mahoney sold 44,400 shares of the stock in a transaction on Monday, August 1st. The stock was sold at an average price of $24.44, for a total value of $1,085,136.00. Following the transaction, the chief executive officer now directly owns 1,388,177 shares in the company, valued at approximately $33,927,045.88. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Boston Scientific Corp. stock. Bank of Montreal Can boosted its position in Boston Scientific Corp. (NYSE:BSX) by 18.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 522,744 shares of the company’s stock after buying an additional 80,052 shares during the period. Bank of Montreal Can’s holdings in Boston Scientific Corp. were worth $9,639,000 at the end of the most recent quarter.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.